Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06755086
TF-antigen Targeting Molecular Probe for PET Imaging in Solid Tumors
Sponsor: Peking University Cancer Hospital & Institute
View on ClinicalTrials.gov
Summary
The objective of the study is to construct a noninvasive approach using 124I-labeled monoclonal antibody radiotracer to detect the Thomsen-Friedenreich antigen (TF-antigen, CD176) expression of tumor lesions in patients with solid tumors and to identify patients benefiting from TF-antigen targeting treatment.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
20
Start Date
2025-01-06
Completion Date
2026-12-31
Last Updated
2025-01-01
Healthy Volunteers
No
Conditions
Interventions
DRUG
18-FDG
All study participants will undergo one 18F-FDG PET/ CT scan.
Locations (1)
Beijing Cancer Hospital
Beijing, Beijing Municipality, China